Junli Wu

Junli Wu

Auto-generated profile, based on publicly available information

Junli Wu

Department of Endocrinology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, People’s Republic of China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2026 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
HFHongyan Fan
Hongyan Fan
JWJunli Wu
Junli Wu
YSYufen Shen
Yufen Shen
WZWenwen Zheng
Wenwen Zheng
Heart failure with preserved ejection fraction (HFpEF) is rapidly emerging as a predominant form of heart failure worldwide. Its pathogenesis extends beyond traditional hemodynamic abnormalities and involves multiple pathways, such as systemic metabolism, inflammation, and endothelial dysfunction. Type 2 diabetes mellitus (T2DM), which is present in up to 45% of patients with HFpEF, is one of the most common and clinically important comorbidities of HFpEF. T2DM not only significantly increases its incidence but also leads to more severe complications and poorer prognosis, constituting a distinct clinical phenotype known as "diabetic HFpEF.” In recent years, the role of the gut microbiota (GMB) as a central hub linking metabolism and the cardiovascular system has become increasingly prominent. This review summarizes the epidemiological and pathophysiological connections between T2DM and HFpEF, with a focus on characteristic alterations in gut dysbiosis in patients with diabetic HFpEF and the underlying mechanisms involving microbiota-derived metabolites, including short-chain fatty acids (SCFAs), trimethylamine N-oxide (TMAO), and bile acids (BAs). It also discusses how the cardiovascular protective effects of novel antidiabetic drugs are closely related to their potential mechanisms of modulating gut microbiota ecology and restoring metabolic balance. However, current evidence remains largely mechanistic and observational, and the causal relationships between gut dysbiosis and diabetic HFpEF require further validation. Overall, GMB represents an important and modifiable target in patients with diabetic HFpEF, offering new directions for both mechanistic research and therapeutic interventions.

26 June 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
JWJunli Wu
Junli Wu
WZWenwen Zheng
Wenwen Zheng
QQQianxian Qi
Qianxian Qi
HCHe Chaojie
He Chaojie
CZchanglin zhai
changlin zhai
HFHongyan Fan
Hongyan Fan
Heart failure with preserved ejection fraction (HFpEF) has emerged as the predominantform of heart failure (HF) worldwide and is increasingly recognized as a systemic syndrome closely linked to metabolic dysfunction. Furthermore, metabolic dysfunction–associated steatotic liver disease (MASLD), a highly prevalent yet often underrecognized comorbidity in patients with HFpEF, has attracted increasing attention. Accumulating epidemiological evidence demonstrates a significant association between MASLD and HFpEF, suggesting shared pathophysiological foundations that extend beyond coincidental coexistence. Mechanistically, MASLD contributes to the development and progression of HFpEF through a network of interconnected pathways, including chronic low-grade inflammation, insulin resistance (IR), dysregulated lipid metabolism, endothelial dysfunction, the gut–liver–heart axis, and as liver-derived mediators that influence cardiac structure and function. These overlapping mechanisms underlie the pronounced clinical and phenotypic heterogeneity of HFpEF and may help explain the limited efficacy of conventional heart failure therapies. This review summarizes current diagnostic and therapeutic strategies for HFpEF and MASLD and proposes an integrated, multiorgan framework to improve clinical recognition and management. A deeper understanding of liver–heart interactions is essential to redefining cardiometabolic disease, shifting from an organ-centric perspective toward a more integrated, mechanism-based approach.